Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Income: 2022-2024

Historic Net Income for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $65.6 million.

  • Entrada Therapeutics' Net Income fell 215.75% to -$44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 288.29%. This contributed to the annual value of $65.6 million for FY2024, which is 1087.80% up from last year.
  • Per Entrada Therapeutics' latest filing, its Net Income stood at $65.6 million for FY2024, which was up 1,087.80% from -$6.6 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Net Income registered a high of $65.6 million during FY2024, and its lowest value of -$94.6 million during FY2022.
  • Its 3-year average for Net Income is -$11.9 million, with a median of -$6.6 million in 2023.
  • Data for Entrada Therapeutics' Net Income shows a peak YoY surged of 1,087.80% (in 2024) over the last 5 years.
  • Entrada Therapeutics' Net Income (Yearly) stood at -$94.6 million in 2022, then spiked by 92.98% to -$6.6 million in 2023, then spiked by 1,087.80% to $65.6 million in 2024.